


Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  	Atty. Docket No. 01-1693-O	Serial No. 09/896,139
	Applicant: Beck, et al.	
	Filing Date: June 29, 2001	Group: 1624

### FOREIGN PATENT DOCUMENTS

Examiner Initial	No.	Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
RR	1.	WO 99/65870	12/23/99	PCT	—	—		
RR	2.	WO 96/22287	7/25/96	PCT	—	—		
RR	3.	EP 0, 432, 694	6/19/91	Europe	—	—		

### OTHER DOCUMENTS - Including Author, Title, Date, Pertinent Pages, Etc.

Examiner Initial	No.	
RR	4.	Chevallier N. et al., Cathepsin D displays in vitro $\beta$ -secretase-like specificity, Brain Research 750 (1997), pages 11-19
RR	5.	Getman D.P. et al., Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere, Journal of Medicinal Chemistry, 1993, 36 pages, 288-291
RR	6.	Kick E.K. et al., Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsin D, Chemistry and Biology, April 1997, 4:297-307
RR	7.	Ng J.S. et al., A practical synthesis of an HIV protease inhibitor intermediate – Diastereoselective epoxide formation from chiral $\alpha$ -aminoaldehydes, Tetrahedron Vol 51, No 23, pages 6397-6410, 1995

RECEIVED

DEC 19 2002

TECH CENTER 1600/2900

Examiner <i>RR</i>	Date Considered <i>1-11-03</i>
--------------------	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.